Complement Therapeutics ^Peer

Complement Therapeutics, also known as Complement Therapeutics GmbH, is an early-stage biotechnology company based in Munich, Germany, with an additional presence in London, England. The company specializes in the research and development of novel therapeutics for complement-mediated diseases, leveraging pioneering research from the University of Manchester.

The company is focused on addressing unmet needs in diseases related to complement dysregulation. Its lead investigational product, CTx001, is being evaluated as a potential gene therapy for geographic atrophy, a major cause of blindness linked to dry age-related macular degeneration. Complement Therapeutics has also developed the Complement Precision Medicine (CPM) platform, which utilizes mass spectrometry to measure multiple complement cascade proteins from blood samples, enhancing diagnosis and monitoring of related diseases.

In April 2023, Complement Therapeutics secured €72 million in Series A financing to support its initiatives. The company has established a strategic manufacturing partnership with Pharmaron to advance its therapeutic pipeline.